Allena Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass. – Jan. 8, 2016 - Allena Pharmaceuticals, a specialty biopharmaceutical company focused on developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, announced today thatAlexey Margolin, Ph.D., president and chief executive officer of Allena, will provide a corporate presentation at the 34th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. PT (2:30 p.m. ET), on Thursday, January 14, 2016, in the Elizabethan D room at the Westin St. Francis Hotel in San Francisco.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases. Allena is currently conducting two additional Phase 2 clinical trials of its lead product candidate, ALLN-177, in patients with hyperoxaluria. The company’s technological approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by degrading metabolites, without being absorbed into the bloodstream. Led by a proven management team with deep expertise in protein therapeutic design and development, Allena is committed to bringing breakthrough new treatments to patients with unmet medical needs. Based in Newton, Mass., the company is supported by a top-tier investor syndicate including Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners, HBM Partners, Pharmstandard International, S.A , Partner Fund Management, Fidelity Management & Research Company, and other investors. For more information, please visit www.allenapharma.com.
Manager of Corporate Operations (617) 467-4577 firstname.lastname@example.org